LinkedInXFacebook
Subscribe
Orthopedics This Week
  • Opinions
  • |My Feed
  • |Events
  • |Company Directory
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Globus Medical Profits Climb as Sales Slip
Company News

Globus Medical Profits Climb as Sales Slip

By Robin YoungNovember 17, 2026 3 min read Premium comments

Advertisement

Globus Medical Profits Climb as Sales Slip

For the quarter ended September 30, 2026, Globus posted $763.7 million in sales, down 0.7% from a year earlier.

Net income increased 18.7% to $141.2 million.

This is a wealth creation company – and, by ‘wealth creation’, we’re referring to more cash profits, versus Wall Street’s business model of finding a greater fool to buy stock.

The Quarter at a Glance

Dollars in millions. Quarterly results are for the three months ended September 30; cash balances are as of September 30.

Financial MeasureQ3 2026Q3 2025Change
Sales$763.7$769.0−0.7%
Gross profit$509.2$493.9+3.1%
Operating profit$177.6$137.4+29.3%
EBITDA$245.8$213.7+15.0%
Free cash flow$224.8$213.9+5.1%
Cash on hand$441.3$371.8+18.7%

Gross profit and operating profit are GAAP figures. EBITDA is before the company’s additional adjustments; EBITDA and free cash flow are non-GAAP measures. Cash on hand comprises cash and cash equivalents, excluding restricted cash and marketable securities.

The Good News: Core Sales Rose. The Bad News: Nevro Sales Collapsed

For the quarter, Globus’s base business sales, excluding Nevro, rose 3.0% to $690.0 million.

Nevro, however, lost 25.7% of its business coming in at $73.7 million from $99.3 million last year.

International sales were also a drag on sales growth, falling 5.7% to $142.7 million. U.S. sales edged up 0.5% to $621.0 million.

President and CEO Keith Pfeil said U.S. Spine grew 2% against double-digit growth in the comparable 2025 quarter. He pointed to average growth in the mid-single digits over two years as evidence that Globus continues to capture market share.

Advertisement

Robots Supply the Momentum

Enabling Technologies delivered the liveliest growth. Revenue increased 24.3% to $34.9 million, while Globus deployed 73% more robot and navigation units than a year earlier.

Pfeil described a strategy connecting and integrating patient selection, surgical techniques, complementary implants and technology across the procedure landscape as the flywheel driving sales growth and market penetration.

Margins Improve the Earnings Picture

Globus retained more profit from each sales dollar.

GAAP gross margin rose to 66.7% from 64.2%. Adjusted gross margin reached 69.5%, up 1.4 percentage points. CFO Kyle Kline said this marked the eighth consecutive quarter of sequential improvement in adjusted gross margin.

Operating profit increased 29.3% to $177.6 million, lifting operating margin to 23.2% from 17.9%. Selling, general and administrative expenses declined $25.1 million, while research and development spending fell $3.5 million.

Lower litigation provisions also helped the earnings comparison, falling to $3.7 million from $28.3 million. That contributes to the difference between the growth in reported and adjusted earnings. GAAP diluted earnings per share rose 18.2% to $1.04, while adjusted EPS increased to $1.23 from $1.18.

Adjusted EBITDA rose 3.8% to $262.2 million, with its margin improving to 34.3% from 32.8%. Globus’s adjusted measure excludes additional items such as stock compensation and litigation provisions.

Cash Gives the Buyback Room

Operating cash flow reached $265.2 million. After $40.4 million in capital expenditures, free cash flow totaled $224.8 million, up 5.1%.

Cash and cash equivalents stood at $441.3 million, compared with $371.8 million a year earlier. Including short- and long-term marketable securities, Globus held $871.2 million, excluding restricted cash.

Advertisement

On November 2, the board increased the existing share repurchase authorization by $500 million.

Globus had already repurchased $279.0 million of shares during the first nine months of 2026. The expanded authorization gives management more flexibility to return cash to shareholders while considering other investment opportunities.

What will Globus Buy Next?

Globus now expects sales will land at around $3.09 billion for 2026, down from its previous range of $3.18 billion to $3.22 billion. Adjusted EPS guidance remains $4.95 to $5.05, representing growth of 24.4% to 26.9%. Management is asking improved profitability to carry more of the year’s earnings story.

But, of course, the real story is Globus’s steadily rising cash war chest. Remember, cash increased 19% in a down sales Q3 quarter.

What’s GMED going to do with all that cash?

Buy more ortho companies – which are currently trading at historically low valuations and whose owners (looking at you SNN and JNJ) want to move on to next gen shiny objects – metabolic, biologic and pharmacologic products.

Frankly, David Paul can probably manage today’s recon business better than either Namal Nawana (Depuy Synthes) or Deepak Nath (Smith & Nephew).

Source: Globus Medical, Inc.

Author

RY
Robin Young

Why This Matters

Two Perspectives

MBA Lens: Economic and industry impact

Globus Medical reported a slight sales decline of 0.7% to $763.7 million, yet net income surged 18.7% to $141.2 million for Q3 2026. Core business sales, excluding Nevro, grew 3.0%, while Nevro sales collapsed 25.7%. The company's strategy emphasizes profitability and leveraging a growing cash reserve for potential acquisitions, alongside significant share repurchases.

  • U.S. Spine growth and Enabling Technologies (robotics/navigation) revenue increase of 24.3% indicate market share capture and strategic technology adoption.
  • Increased cash on hand and expanded share repurchase authorization signal financial strength and potential for strategic M&A in the orthopedic market.

PhD Lens: Clinical and outcomes impact

Globus Medical's Q3 2026 results showed an 18.7% increase in net income despite a 0.7% sales dip. Enabling Technologies, including robotics and navigation units, demonstrated robust growth of 24.3%, with 73% more units deployed. Conversely, Nevro sales experienced a significant 25.7% decline, impacting overall revenue, while U.S. Spine grew 2%.

  • Growth in Enabling Technologies highlights the increasing adoption and integration of advanced robotic and navigation systems in surgical procedures.
  • The substantial decline in Nevro sales warrants further investigation into clinical efficacy, market acceptance, or competitive landscape factors.
React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

Orthopedics This Week’s mission is to connect the orthopedic community with the people, ideas, and innovations shaping the future of musculoskeletal care.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Opinions
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, opinions, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy